Global Night Blindness Treatment Market
Global Night Blindness Treatment Market

Night Blindness Treatment Comprehensive Study by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Store), Diagnosis (Blood Tests, Color Vision Testing, Pupil Light Reflex, Electro retinogram (Erg), Others), Symptoms (Eye Pain, Cloudy vision, Halos, Light Sensitivity, Others), Treatment (Medication, Surgery, Others) Players and Region - Global Market Outlook to 2027

Night Blindness Treatment Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Apr 2022 Edition 228 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Night Blindness Treatment?
Night blindness is a situation in which affected humanís journey terrible imaginative and prescient at some point of night time or at dimly lit places. Night blindness as the title suggests does now not suggest that a struggling affected person will totally go blind at night; alternatively it capability that the affected person can also have difficulties seeing or riding at night. Night blindness of one kind is treatable; however, there is no therapy for the different kinds of night time blindness. Night blindness is precipitated due to a range of different imaginative and prescient issues like close to sightedness, cataracts, usher syndrome which is a genetic circumstance affecting each listening to and imaginative and prescient and retinitis pigmentosa which creates tunnel imaginative and prescient due to the darkish pigments amassed in the retina. In some components of the world, night time blindness can additionally be brought about due to the fact of nutrition a deficiency. In order to deal with the treatable kinds of night time blindness, medical doctors may also want full scientific records and look at eyes to appear for the problem. Blood samples may additionally be required to take a look at for the presence of Vitamin A and glucose tiers in the body.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledMerck (United States), Pfizer (United States), GlaxoSmithKline (Canada), Johnson and Johnson Private Limited (India), Roche Holding AG (Switzerland), Abbott (United States), Mylan (United States), Teva Pharmaceuticals (Israel), Sanofi (France) and Novartis (Switzerland)
CAGR%


The market study is broken down, by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Drug Store) and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Night Blindness Treatment market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck (United States), Pfizer (United States), GlaxoSmithKline (Canada), Johnson and Johnson Private Limited (India), Roche Holding AG (Switzerland), Abbott (United States), Mylan (United States), Teva Pharmaceuticals (Israel), Sanofi (France) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bayer (New Jersey), Sun Pharmaceutical Industries (India) and Aurobindo Pharma (India).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Night Blindness Treatment market by Type, Application and Region.

On the basis of geography, the market of Night Blindness Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnosis, the sub-segment i.e. Blood Tests will boost the Night Blindness Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Eye Pain will boost the Night Blindness Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment , the sub-segment i.e. Medication will boost the Night Blindness Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In 2021, Abbott (ABT) has obtained Walk Vascular, a commercial-stage clinical gadget company. Walk Vascular's peripheral thrombectomy structures will be included into the company's endovascular product portfolio. Financial phrases of the deal were no longer disclosed.
In 2021, Merck regarded as MSD backyard the United States and Canada, introduced it has entered into a procurement settlement with the United States authorities for molnupiravir (MK-4482). Molnupiravir is presently being evaluated in a Phase three scientific trial, the MOVe-OUT study, for the cure of non-hospitalized sufferers with laboratory-confirmed COVID-19 and at least one chance thing related with negative ailment outcomes. Merck is creating molnupiravir in collaboration with Ridgeback Bio therapeutics.


Market Drivers
  • Growing Geriatric Population That Is Prone To Vision Loss and Aging Adults
  • Increasing Number of Product Launches

Opportunities
  • Increase in Prevalence of the Disorder

Restraints
  • High Doses of Vitamin A Supplement Can Also Lead To Liver Damage, Dizziness, Severe Nausea and Vomiting
  • Medical Care, Devices and Vision Aids and Caregivers Are Not Cost Effective

Challenges
  • Product Recall


Key Target Audience
Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Merck (United States), Pfizer (United States), GlaxoSmithKline (Canada), Johnson and Johnson Private Limited (India), Roche Holding AG (Switzerland), Abbott (United States), Mylan (United States), Teva Pharmaceuticals (Israel), Sanofi (France) and Novartis (Switzerland) etc.

2. Can we have customized study for Night Blindness Treatment Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Night Blindness Treatment Market by 2027?
Analysts at AMA estimates Night Blindness Treatment Market to reach USD Million by 2027.
Report Objectives / Segmentation Covered
By Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Store
By Diagnosis
  • Blood Tests
  • Color Vision Testing
  • Pupil Light Reflex
  • Electro retinogram (Erg)
  • Others

By Symptoms
  • Eye Pain
  • Cloudy vision
  • Halos
  • Light Sensitivity
  • Others

By Treatment
  • Medication
  • Surgery
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population That Is Prone To Vision Loss and Aging Adults
      • 3.2.2. Increasing Number of Product Launches
    • 3.3. Market Challenges
      • 3.3.1. Product Recall
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Night Blindness Treatment, by Application, Diagnosis, Symptoms, Treatment and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Night Blindness Treatment (Value)
      • 5.2.1. Global Night Blindness Treatment by: Application (Value)
        • 5.2.1.1. Hospital Pharmacies
        • 5.2.1.2. Retail Pharmacies
        • 5.2.1.3. Online Pharmacies
        • 5.2.1.4. Drug Store
      • 5.2.2. Global Night Blindness Treatment by: Diagnosis (Value)
        • 5.2.2.1. Blood Tests
        • 5.2.2.2. Color Vision Testing
        • 5.2.2.3. Pupil Light Reflex
        • 5.2.2.4. Electro retinogram (Erg)
        • 5.2.2.5. Others
      • 5.2.3. Global Night Blindness Treatment by: Symptoms (Value)
        • 5.2.3.1. Eye Pain
        • 5.2.3.2. Cloudy vision
        • 5.2.3.3. Halos
        • 5.2.3.4. Light Sensitivity
        • 5.2.3.5. Others
      • 5.2.4. Global Night Blindness Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Night Blindness Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson and Johnson Private Limited (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche Holding AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceuticals (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Night Blindness Treatment Sale, by Application, Diagnosis, Symptoms, Treatment and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Night Blindness Treatment (Value)
      • 7.2.1. Global Night Blindness Treatment by: Application (Value)
        • 7.2.1.1. Hospital Pharmacies
        • 7.2.1.2. Retail Pharmacies
        • 7.2.1.3. Online Pharmacies
        • 7.2.1.4. Drug Store
      • 7.2.2. Global Night Blindness Treatment by: Diagnosis (Value)
        • 7.2.2.1. Blood Tests
        • 7.2.2.2. Color Vision Testing
        • 7.2.2.3. Pupil Light Reflex
        • 7.2.2.4. Electro retinogram (Erg)
        • 7.2.2.5. Others
      • 7.2.3. Global Night Blindness Treatment by: Symptoms (Value)
        • 7.2.3.1. Eye Pain
        • 7.2.3.2. Cloudy vision
        • 7.2.3.3. Halos
        • 7.2.3.4. Light Sensitivity
        • 7.2.3.5. Others
      • 7.2.4. Global Night Blindness Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Night Blindness Treatment: by Application(USD Million)
  • Table 2. Night Blindness Treatment Hospital Pharmacies , by Region USD Million (2016-2021)
  • Table 3. Night Blindness Treatment Retail Pharmacies , by Region USD Million (2016-2021)
  • Table 4. Night Blindness Treatment Online Pharmacies , by Region USD Million (2016-2021)
  • Table 5. Night Blindness Treatment Drug Store , by Region USD Million (2016-2021)
  • Table 6. Night Blindness Treatment: by Diagnosis(USD Million)
  • Table 7. Night Blindness Treatment Blood Tests , by Region USD Million (2016-2021)
  • Table 8. Night Blindness Treatment Color Vision Testing , by Region USD Million (2016-2021)
  • Table 9. Night Blindness Treatment Pupil Light Reflex , by Region USD Million (2016-2021)
  • Table 10. Night Blindness Treatment Electro retinogram (Erg) , by Region USD Million (2016-2021)
  • Table 11. Night Blindness Treatment Others , by Region USD Million (2016-2021)
  • Table 12. Night Blindness Treatment: by Symptoms(USD Million)
  • Table 13. Night Blindness Treatment Eye Pain , by Region USD Million (2016-2021)
  • Table 14. Night Blindness Treatment Cloudy vision , by Region USD Million (2016-2021)
  • Table 15. Night Blindness Treatment Halos , by Region USD Million (2016-2021)
  • Table 16. Night Blindness Treatment Light Sensitivity , by Region USD Million (2016-2021)
  • Table 17. Night Blindness Treatment Others , by Region USD Million (2016-2021)
  • Table 18. South America Night Blindness Treatment, by Country USD Million (2016-2021)
  • Table 19. South America Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 20. South America Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 21. South America Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 22. South America Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 23. Brazil Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 24. Brazil Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 25. Brazil Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 26. Brazil Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 27. Argentina Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 28. Argentina Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 29. Argentina Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 30. Argentina Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 31. Rest of South America Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 32. Rest of South America Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 33. Rest of South America Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 34. Rest of South America Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 35. Asia Pacific Night Blindness Treatment, by Country USD Million (2016-2021)
  • Table 36. Asia Pacific Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 37. Asia Pacific Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 38. Asia Pacific Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 39. Asia Pacific Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 40. China Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 41. China Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 42. China Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 43. China Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 44. Japan Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 45. Japan Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 46. Japan Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 47. Japan Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 48. India Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 49. India Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 50. India Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 51. India Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 52. South Korea Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 53. South Korea Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 54. South Korea Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 55. South Korea Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 56. Taiwan Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 57. Taiwan Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 58. Taiwan Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 59. Taiwan Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 60. Australia Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 61. Australia Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 62. Australia Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 63. Australia Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 68. Europe Night Blindness Treatment, by Country USD Million (2016-2021)
  • Table 69. Europe Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 70. Europe Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 71. Europe Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 72. Europe Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 73. Germany Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 74. Germany Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 75. Germany Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 76. Germany Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 77. France Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 78. France Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 79. France Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 80. France Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 81. Italy Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 82. Italy Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 83. Italy Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 84. Italy Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 85. United Kingdom Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 86. United Kingdom Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 87. United Kingdom Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 88. United Kingdom Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 89. Netherlands Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 90. Netherlands Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 91. Netherlands Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 92. Netherlands Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 93. Rest of Europe Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 94. Rest of Europe Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 95. Rest of Europe Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 96. Rest of Europe Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 97. MEA Night Blindness Treatment, by Country USD Million (2016-2021)
  • Table 98. MEA Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 99. MEA Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 100. MEA Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 101. MEA Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 102. Middle East Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 103. Middle East Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 104. Middle East Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 105. Middle East Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 106. Africa Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 107. Africa Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 108. Africa Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 109. Africa Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 110. North America Night Blindness Treatment, by Country USD Million (2016-2021)
  • Table 111. North America Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 112. North America Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 113. North America Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 114. North America Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 115. United States Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 116. United States Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 117. United States Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 118. United States Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 119. Canada Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 120. Canada Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 121. Canada Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 122. Canada Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 123. Mexico Night Blindness Treatment, by Application USD Million (2016-2021)
  • Table 124. Mexico Night Blindness Treatment, by Diagnosis USD Million (2016-2021)
  • Table 125. Mexico Night Blindness Treatment, by Symptoms USD Million (2016-2021)
  • Table 126. Mexico Night Blindness Treatment, by Treatment USD Million (2016-2021)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Night Blindness Treatment: by Application(USD Million)
  • Table 138. Night Blindness Treatment Hospital Pharmacies , by Region USD Million (2022-2027)
  • Table 139. Night Blindness Treatment Retail Pharmacies , by Region USD Million (2022-2027)
  • Table 140. Night Blindness Treatment Online Pharmacies , by Region USD Million (2022-2027)
  • Table 141. Night Blindness Treatment Drug Store , by Region USD Million (2022-2027)
  • Table 142. Night Blindness Treatment: by Diagnosis(USD Million)
  • Table 143. Night Blindness Treatment Blood Tests , by Region USD Million (2022-2027)
  • Table 144. Night Blindness Treatment Color Vision Testing , by Region USD Million (2022-2027)
  • Table 145. Night Blindness Treatment Pupil Light Reflex , by Region USD Million (2022-2027)
  • Table 146. Night Blindness Treatment Electro retinogram (Erg) , by Region USD Million (2022-2027)
  • Table 147. Night Blindness Treatment Others , by Region USD Million (2022-2027)
  • Table 148. Night Blindness Treatment: by Symptoms(USD Million)
  • Table 149. Night Blindness Treatment Eye Pain , by Region USD Million (2022-2027)
  • Table 150. Night Blindness Treatment Cloudy vision , by Region USD Million (2022-2027)
  • Table 151. Night Blindness Treatment Halos , by Region USD Million (2022-2027)
  • Table 152. Night Blindness Treatment Light Sensitivity , by Region USD Million (2022-2027)
  • Table 153. Night Blindness Treatment Others , by Region USD Million (2022-2027)
  • Table 154. South America Night Blindness Treatment, by Country USD Million (2022-2027)
  • Table 155. South America Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 156. South America Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 157. South America Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 158. South America Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 159. Brazil Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 160. Brazil Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 161. Brazil Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 162. Brazil Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 163. Argentina Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 164. Argentina Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 165. Argentina Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 166. Argentina Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 167. Rest of South America Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 168. Rest of South America Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 169. Rest of South America Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 170. Rest of South America Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 171. Asia Pacific Night Blindness Treatment, by Country USD Million (2022-2027)
  • Table 172. Asia Pacific Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 173. Asia Pacific Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 174. Asia Pacific Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 175. Asia Pacific Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 176. China Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 177. China Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 178. China Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 179. China Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 180. Japan Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 181. Japan Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 182. Japan Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 183. Japan Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 184. India Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 185. India Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 186. India Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 187. India Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 188. South Korea Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 189. South Korea Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 190. South Korea Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 191. South Korea Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 192. Taiwan Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 193. Taiwan Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 194. Taiwan Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 195. Taiwan Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 196. Australia Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 197. Australia Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 198. Australia Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 199. Australia Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 200. Rest of Asia-Pacific Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 201. Rest of Asia-Pacific Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 203. Rest of Asia-Pacific Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 204. Europe Night Blindness Treatment, by Country USD Million (2022-2027)
  • Table 205. Europe Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 206. Europe Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 207. Europe Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 208. Europe Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 209. Germany Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 210. Germany Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 211. Germany Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 212. Germany Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 213. France Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 214. France Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 215. France Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 216. France Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 217. Italy Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 218. Italy Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 219. Italy Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 220. Italy Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 221. United Kingdom Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 222. United Kingdom Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 223. United Kingdom Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 224. United Kingdom Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 225. Netherlands Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 226. Netherlands Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 227. Netherlands Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 228. Netherlands Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 229. Rest of Europe Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 230. Rest of Europe Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 231. Rest of Europe Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 232. Rest of Europe Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 233. MEA Night Blindness Treatment, by Country USD Million (2022-2027)
  • Table 234. MEA Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 235. MEA Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 236. MEA Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 237. MEA Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 238. Middle East Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 239. Middle East Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 240. Middle East Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 241. Middle East Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 242. Africa Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 243. Africa Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 244. Africa Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 245. Africa Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 246. North America Night Blindness Treatment, by Country USD Million (2022-2027)
  • Table 247. North America Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 248. North America Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 249. North America Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 250. North America Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 251. United States Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 252. United States Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 253. United States Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 254. United States Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 255. Canada Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 256. Canada Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 257. Canada Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 258. Canada Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 259. Mexico Night Blindness Treatment, by Application USD Million (2022-2027)
  • Table 260. Mexico Night Blindness Treatment, by Diagnosis USD Million (2022-2027)
  • Table 261. Mexico Night Blindness Treatment, by Symptoms USD Million (2022-2027)
  • Table 262. Mexico Night Blindness Treatment, by Treatment USD Million (2022-2027)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Night Blindness Treatment: by Application USD Million (2016-2021)
  • Figure 5. Global Night Blindness Treatment: by Diagnosis USD Million (2016-2021)
  • Figure 6. Global Night Blindness Treatment: by Symptoms USD Million (2016-2021)
  • Figure 7. South America Night Blindness Treatment Share (%), by Country
  • Figure 8. Asia Pacific Night Blindness Treatment Share (%), by Country
  • Figure 9. Europe Night Blindness Treatment Share (%), by Country
  • Figure 10. MEA Night Blindness Treatment Share (%), by Country
  • Figure 11. North America Night Blindness Treatment Share (%), by Country
  • Figure 12. Global Night Blindness Treatment share by Players 2021 (%)
  • Figure 13. Global Night Blindness Treatment share by Players (Top 3) 2021(%)
  • Figure 14. Global Night Blindness Treatment share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 17. Merck (United States) Revenue: by Geography 2021
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2021
  • Figure 20. GlaxoSmithKline (Canada) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline (Canada) Revenue: by Geography 2021
  • Figure 22. Johnson and Johnson Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 23. Johnson and Johnson Private Limited (India) Revenue: by Geography 2021
  • Figure 24. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche Holding AG (Switzerland) Revenue: by Geography 2021
  • Figure 26. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 27. Abbott (United States) Revenue: by Geography 2021
  • Figure 28. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 29. Mylan (United States) Revenue: by Geography 2021
  • Figure 30. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva Pharmaceuticals (Israel) Revenue: by Geography 2021
  • Figure 32. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi (France) Revenue: by Geography 2021
  • Figure 34. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 36. Global Night Blindness Treatment: by Application USD Million (2022-2027)
  • Figure 37. Global Night Blindness Treatment: by Diagnosis USD Million (2022-2027)
  • Figure 38. Global Night Blindness Treatment: by Symptoms USD Million (2022-2027)
  • Figure 39. South America Night Blindness Treatment Share (%), by Country
  • Figure 40. Asia Pacific Night Blindness Treatment Share (%), by Country
  • Figure 41. Europe Night Blindness Treatment Share (%), by Country
  • Figure 42. MEA Night Blindness Treatment Share (%), by Country
  • Figure 43. North America Night Blindness Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Merck (United States)
  • Pfizer (United States)
  • GlaxoSmithKline (Canada)
  • Johnson and Johnson Private Limited (India)
  • Roche Holding AG (Switzerland)
  • Abbott (United States)
  • Mylan (United States)
  • Teva Pharmaceuticals (Israel)
  • Sanofi (France)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
Bayer (New Jersey) , Sun Pharmaceutical Industries (India) , Aurobindo Pharma (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation